-$0.69 EPS Expected for PolyPid Ltd. (NASDAQ:PYPD) This Quarter

Analysts expect PolyPid Ltd. (NASDAQ:PYPDGet Rating) to post earnings per share of ($0.69) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for PolyPid’s earnings. PolyPid posted earnings of ($0.56) per share during the same quarter last year, which would indicate a negative year over year growth rate of 23.2%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that PolyPid will report full-year earnings of ($2.41) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.39). For the next financial year, analysts expect that the business will report earnings of ($2.11) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow PolyPid.

PolyPid (NASDAQ:PYPDGet Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the prior year, the business posted ($0.47) earnings per share.

PYPD has been the subject of several research analyst reports. Raymond James decreased their price target on shares of PolyPid from $23.00 to $17.00 and set a “strong-buy” rating for the company in a report on Friday, February 11th. Zacks Investment Research cut shares of PolyPid from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th.

Shares of NASDAQ:PYPD opened at $5.07 on Tuesday. The company has a 50 day moving average of $5.25 and a 200-day moving average of $5.52. The stock has a market cap of $86.42 million, a price-to-earnings ratio of -2.09 and a beta of 0.83. PolyPid has a one year low of $3.92 and a one year high of $9.64.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of PolyPid by 12.2% during the third quarter. Geode Capital Management LLC now owns 12,545 shares of the company’s stock valued at $97,000 after acquiring an additional 1,364 shares during the last quarter. Silverarc Capital Management LLC grew its holdings in shares of PolyPid by 1.2% during the first quarter. Silverarc Capital Management LLC now owns 218,175 shares of the company’s stock valued at $1,191,000 after buying an additional 2,555 shares during the last quarter. Morgan Stanley acquired a new position in shares of PolyPid during the second quarter valued at about $32,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of PolyPid by 17.0% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 28,499 shares of the company’s stock valued at $164,000 after purchasing an additional 4,138 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of PolyPid during the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 20.84% of the company’s stock.

About PolyPid (Get Rating)

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.

Featured Stories

Get a free copy of the Zacks research report on PolyPid (PYPD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.